Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.

Stryjewski ME, O'Riordan WD, Lau WK, Pien FD, Dunbar LM, Vallee M, Fowler VG Jr, Chu VH, Spencer E, Barriere SL, Kitt MM, Cabell CH, Corey GR; FAST Investigator Group..

Clin Infect Dis. 2005 Jun 1;40(11):1601-7. Epub 2005 Apr 28.

PMID:
15889357
2.

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.

Higgins DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, Sandvik E, Hubbard JM, Kaniga K, Schmidt DE Jr, Gao Q, Cass RT, Karr DE, Benton BM, Humphrey PP.

Antimicrob Agents Chemother. 2005 Mar;49(3):1127-34.

3.

Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey.

Deresinski S.

Clin Infect Dis. 2005 Feb 15;40(4):562-73. Epub 2005 Jan 24. Review.

PMID:
15712079
4.

A clone of methicillin-resistant Staphylococcus aureus among professional football players.

Kazakova SV, Hageman JC, Matava M, Srinivasan A, Phelan L, Garfinkel B, Boo T, McAllister S, Anderson J, Jensen B, Dodson D, Lonsway D, McDougal LK, Arduino M, Fraser VJ, Killgore G, Tenover FC, Cody S, Jernigan DB.

N Engl J Med. 2005 Feb 3;352(5):468-75.

5.

Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects.

Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S.

Antimicrob Agents Chemother. 2005 Jan;49(1):195-201.

6.

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

National Nosocomial Infections Surveillance System..

Am J Infect Control. 2004 Dec;32(8):470-85. No abstract available.

PMID:
15573054
7.

Staphylococcus aureus with reduced susceptibility to vancomycin.

Cosgrove SE, Carroll KC, Perl TM.

Clin Infect Dis. 2004 Aug 15;39(4):539-45. Epub 2004 Jul 23. Review.

PMID:
15356818
8.

Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects.

Barriere S, Genter F, Spencer E, Kitt M, Hoelscher D, Morganroth J.

J Clin Pharmacol. 2004 Jul;44(7):689-95.

PMID:
15199073
9.

Trends in antimicrobial drug development: implications for the future.

Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr.

Clin Infect Dis. 2004 May 1;38(9):1279-86. Epub 2004 Apr 14.

PMID:
15127341
10.

Vancomycin-resistant Staphylococcus aureus--New York, 2004.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2004 Apr 23;53(15):322-3.

12.

In vitro activity of TD-6424 against Staphylococcus aureus.

Pace JL, Krause K, Johnston D, Debabov D, Wu T, Farrington L, Lane C, Higgins DL, Christensen B, Judice JK, Kaniga K.

Antimicrob Agents Chemother. 2003 Nov;47(11):3602-4.

13.
14.

Effects of three fluoroquinolones on QT interval in healthy adults after single doses.

Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R.

Clin Pharmacol Ther. 2003 Apr;73(4):292-303.

PMID:
12709719
15.

Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin.

Dufour P, Gillet Y, Bes M, Lina G, Vandenesch F, Floret D, Etienne J, Richet H.

Clin Infect Dis. 2002 Oct 1;35(7):819-24. Epub 2002 Sep 3.

PMID:
12228818
16.

Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998.

Naimi TS, LeDell KH, Boxrud DJ, Groom AV, Steward CD, Johnson SK, Besser JM, O'Boyle C, Danila RN, Cheek JE, Osterholm MT, Moore KA, Smith KE.

Clin Infect Dis. 2001 Oct 1;33(7):990-6. Epub 2001 Sep 5.

PMID:
11528570
17.

Staphylococcus aureus infections.

Lowy FD.

N Engl J Med. 1998 Aug 20;339(8):520-32. Review. No abstract available.

PMID:
9709046
18.

Historical yearly usage of vancomycin.

Kirst HA, Thompson DG, Nicas TI.

Antimicrob Agents Chemother. 1998 May;42(5):1303-4. No abstract available.

19.

Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk.

Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, Boyle-Vavra S, Leitch CD, Daum RS.

JAMA. 1998 Feb 25;279(8):593-8.

PMID:
9486753

Supplemental Content

Support Center